IGF2R Human shRNA Lentiviral Particle (Locus ID 3482)

CAT#: TL312220V

IGF2R - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL312220A virus into HEK293 cells. TL312220A virus was prepared using lenti-shRNA TL312220A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL312220B virus into HEK293 cells. TL312220B virus was prepared using lenti-shRNA TL312220B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL312220C] virus into HEK293 cells. [TL312220C] virus was prepared using lenti-shRNA [TL312220C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL312220D] virus into HEK293 cells. [TL312220D] virus was prepared using lenti-shRNA [TL312220D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 3482
• Synonyms: CD222; CI-M6PR; CIMPR; M6P-R; M6P/IGF2R; MPR1; MPR 300; MPR300; MPRI
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_000876, NM_000876.1, NM_000876.2, NM_000876.3, BC010121, BC172256, NM_000876.4
• UniProt ID: P11717
• Summary: This gene encodes a receptor for both insulin-like growth factor 2 and mannose 6-phosphate. The binding sites for each ligand are located on different segments of the protein. This receptor has various functions, including in the intracellular trafficking of lysosomal enzymes, the activation of transforming growth factor beta, and the degradation of insulin-like growth factor 2. Mutation or loss of heterozygosity of this gene has been association with risk of hepatocellular carcinoma. The orthologous mouse gene is imprinted and shows exclusive expression from the maternal allele; however, imprinting of the human gene may be polymorphic, as only a minority of individuals showed biased expression from the maternal allele (PMID:8267611). [provided by RefSeq, Nov 2015]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).